Background Statin treatment and variants in the gene encoding HMG-CoA reductase are associated with reductions in both the concentration of LDL cholesterol and the risk of coronary heart disease, but also with modest hyperglycaemia, increased bodyweight, and modestly increased risk of type 2 diabetes, which in no way off sets their substantial benefi ts. We sought to investigate the associations of LDL cholesterol-lowering PCSK9 variants with type 2 diabetes and related biomarkers to gauge the likely eff ects of PCSK9 inhibitors on diabetes risk.
Introduction
The benefi t of statins in reducing LDL cholesterol and coronary heart disease (CHD) risk is well established. More recently, and only after completion of numerous randomised controlled trials, was it discovered that statins increase risk of type 2 diabetes, 1,2 although this eff ect is modest and greatly outweighed by the benefi ts of this drug class. Genetic studies based on common variants in the gene encoding the target of statins, HMG-CoA reductase (HMGCR), suggest the eff ect is mechanism-based (ie, on-target). 3 Genetic studies assessing the eff ects of variants in a broader range of genes suggest a more general link between lower LDL cholesterol and higher risk of type 2 diabetes. 4, 5 Consistent with this fi nding, patients with autosomal dominant familial hypercholesterolaemia caused by mutations in the LDL receptor and apolipoprotein B genes are 50% less likely to be diagnosed with type 2 diabetes compared with their unaff ected relatives. 6 Gain-of-function mutations in PCSK9, the gene encoding proprotein convertase subtilisin/kexin type 9, also cause familial hypercholesterolaemia, 7 whereas lossof-function mutations in the same gene lower LDL cholesterol and protect against CHD. 8 Consequently, monoclonal antibodies inhibiting PCSK9 have been developed 9 and are eff ective in lowering LDL cholesterol by 50-70%, 10 with preliminary evidence suggesting that this eff ect might be associated with reduced risk of myocardial infarction and all-cause mortality. 9 Although large phase 3 trials to assess the eff ects of PCSK9 monoclonal antibodies on cardiovascular events are underway, conclusive evidence for the specifi c eff ect of PCSK9 inhibition on risk of type 2 diabetes from individual randomised controlled trials or meta-analyses might not emerge for some time.
We used the principle of mendelian randomisation as a tool for drug target validation, whereby common variants in a gene that encodes a drug target, through eff ects on expression or activity, are used to predict the on-target eff ect of pharmacological modifi cation of the same target. 3, 11, 12 We investigated associations of common genetic variants in PCSK9 with markers of glycaemia, bodyweight, and risk of type 2 diabetes to assess the potential on-target eff ects of PCSK9 inhibition on these traits. Although results of a recent study provided evidence of an association of a single nucleotide polymorphism (SNP) in PCSK9 with type 2 diabetes risk, 13 our aim was to confi rm the type 2 diabetes riskincreasing eff ect of PCSK9 variation and explore potential biological mechanisms that might explain this eff ect. To do this we used four SNPs in the PCSK9 locus collected in 50 studies supplemented with data from large genetic consortia.
Methods

Genetic variant selection
We selected four SNPs in or near PCSK9 on the basis of a strong association with LDL cholesterol, as reported by the Global Lipids Genetics Consortium (GLGC); 14 low pairwise linkage disequilibrium (r²≤0·30) with SNPs within the same and adjacent genes (1000 Genomes CEU data); high prior probability of being a functional variant based on the combined annotation dependent depletion (CADD) score, or the SNP being non-synonymous, or both; 15 or previous reported associations with CHD. 16 On the basis of these criteria, we selected the SNPs rs11583680 (minor allele frequency 0·14), rs11591147 (0·01), rs2479409 (0·36), and rs11206510 (0·17; appendix).
Individual participant-level and summary-level data
Data were analysed from two sources. Participating studies executed a common analysis script on their own data, submitting summary estimates to a central analysis centre at University College London, London, UK. Main to assess their eff ect on cardiovascular outcomes are ongoing, but reliable evidence for a possible association between PCSK9 inhibition and risk of diabetes could take longer to accrue.
Added value of this study
Mendelian randomisation is an established approach that uses randomly allocated variants in the encoding gene to infer mechanism-based effi cacy and safety outcomes from pharmacological perturbation of a drug target. We used four genetic variants in PCSK9 in more than 550 000 individuals (including about 50 000 diabetes cases) and showed that PCSK9 genetic variants associated with lower LDL cholesterol concentrations were associated with increased concentration of fasting glucose, bodyweight, and risk of diabetes. This fi nding adds robust new evidence to previous research that identifi ed weak associations of PCSK9 with risk of diabetes.
Implications of all the available evidence
Similar to statin therapy, treatment with PCSK9 inhibitors is likely to increase the risk of diabetes. Patients treated with PCSK9 inhibitors should be carefully monitored for dysglycaemia, including within ongoing and future clinical trials.
eff ect estimates from the participating studies were then meta-analysed with pooled summary estimates from the public domain data repositories of relevant genetic (genome-wide association study [GWAS] ) consortia, but only if the study-level estimates had not previously contributed to consortia results, to prevent double counting. All studies contributing data to these analyses were approved by their local ethics committees.
Data were collected for LDL cholesterol, insulin (fasting and non-fasting), glucose (fasting and non-fasting), HbA 1c , insulin resistance and secretion via basal homeostatic model assessments (HOMA-IR and HOMA-B), bodyweight, height, BMI, waist-to-hip ratio, and history or incidence of type 2 diabetes.
Publicly available summary-level data were available on blood lipids from the GLGC; 14 type 2 diabetes-related biomarkers (plasma insulin, glucose, HbA 1c , HOMA-IR, and HOMA-B) from the Meta-Analyses of Glucose and Insulin-related traits Consortium (MAGIC); [17] [18] [19] bodyweight, height, BMI, and waist-to-hip ratio from the Genetic Investigation of Anthropometric Traits consortium (GIANT); 20, 21 and type 2 diabetes from the Diabetes Genetics Replication and Meta-analysis consortium (DIAGRAM) 22 and Exome chip 80K. 23 Additionally, crosssectional data were obtained for adiposity traits and the prevalence of type 2 diabetes from UK Biobank.
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Statistical analyses
In all analyses we assumed an additive allele eff ect with genotypes coded as 0, 1, and 2, representing the number of minor alleles. We analysed continuous biomarkers using linear regression models; the composite endpoint of prevalent or incident type 2 diabetes was analysed with logistic regression. Study-specifi c associations were pooled for each SNP by use of the inverse-variance weighted method for fi xed-eff ect and random-eff ects meta-analysis. We assessed between-study heterogeneity using the Q-test and the I² statistic 25 with a one-sided upper 97·5% CI. Study-specifi c associations were excluded if the SNP was not in Hardy-Weinberg equilibrium (appendix).
Our approach to SNP selection was designed to prune the number of SNPs at PCSK9 used in the analysis, without loss of information. We decided a priori to combine the four approximately independent SNPs in a weighted gene-centric score (GS) using the inversevariance weighted method for fi xed and random eff ects. 26 The GS provides a more precise estimate of the downstream eff ects of variation at PCSK9 by incorporating maximum biological variation. Furthermore, if the four SNP eff ects are homogeneous (assessed by the heterogeneity measures Q-test and I²), the GS estimates will be more powerful and precise compared with individual SNPs in isolation. If, however, the SNP eff ects are heterogeneous (meaning that the PCSK9 eff ects are diff erent according to which part of the gene is assessed), the GS method will be less powerful than the individual SNP tests (depending on the degree of heterogeneity). Our aim was to estimate the eff ect of the PCSK9 locus as a whole, but SNP-specifi c estimates are also reported. Other important assumptions of the GS approach are (approximate) independence of the included SNPs (assessed by pairwise linkage disequilibrium (r²) and use of multivariable regression models) and the additivity of allele eff ects. We also investigated whether the association of individual SNPs with diabetes risk was in proportion to the association with LDL cholesterol lowering.
Estimates are presented as mean diff erences or odds ratios (ORs) with 95% CIs, presented either per LDL cholesterol-decreasing allele or, in the case of GS, per 1 mmol/L (38·67 mg/dL) lower LDL cholesterol. The per 1 mmol/L GS eff ect estimates were derived by multiplying point estimates and their variances by the multiplicative inverse of the estimated SNP-LDL cholesterol eff ects. Similar to most genetic studies, missing data were excluded in an available case manner, assuming a missing-completely-at-random mechanism. 27, 28 To avoid potential bias due to population stratifi cation and nonmodelled ancestry interactions, analyses excluded individuals of non-European ancestry. Diff erences in ancestry can be a potential source of confounding bias (ie, population stratifi cation bias) when environment is related to both the genes and the outcome of interest. Analyses were done with the statistical programme R (version 3.3.0).
Sensitivity analyses
We assumed that the allele eff ects were additive, which we assessed in available individual participant data by comparing an additive model to a non-additive model (allowing for dominance or recessiveness) using a likelihood ratio test (meta-analysed by Fisher's method). 29 Because measurement error might be larger in prevalent cases (ascertained, for example, from hospital records) we did a further sensitivity analysis in which we separately analysed incident and prevalent type 2 diabetes. This sensitivity analysis was done not because we expect the true associations of PCSK9 to be diff erent with respect to prevalent and incident case status, but merely refl ected a quality-control check. Although SNPs were selected to be independent, there was some degree of residual dependency (appendix; maximum r² 0·26). To explore the eff ect of this residual correlation between the four study SNPs (appendix), we compared results from a multivariable analysis (including the four SNPs in the same model) in studies with individual participant data (correcting for this correlation) to pairwise results (ignoring any between-SNP correlation) based on the same data.
Role of the funding source
The funder of the study had no role in study design, data collection, data analysis, data interpretation, or writing of the report. The corresponding author (AFS) had full access Results 50 studies shared participant-level data from up to 245 942 individuals, which was supplemented by summary eff ect estimates from data repositories, resulting in a maximum available sample size of 568 448 indi viduals, including 51 623 cases of incident or prevalent type 2 diabetes. Individual studies were similar with respect to the distribution of biochemical measures (assessed by the median of study-specifi c means): LDL cholesterol 3·41 mmol/L (IQR 0·39), fasting glucose 5·38 mmol/L (0·58), and HbA 1c 5·50% (appendix). Pooled pairwise linkage disequilibrium estimates for the four PCSK9 SNPs all had r² values less than 0·30 (appendix), confi rming that the selected SNPs were in low correlation in the collected data.
The four PCSK9 SNPs were associated with reductions in LDL cholesterol ranging from -0·02 mmol/L (95% CI -0·03 to -0·02) for rs11583680 to -0·34 mmol/L (-0·36 to -0·32) for rs11591147 per LDL cholesteroldecreasing allele (fi gure 1). Figure 2 depicts the associations of the four PCSK9 SNPs after scaling the SNP eff ect to 1 mmol/L lower LDL cholesterol. Results of the PCSK9 GS analysis show that a 1 mmol/L lower LDL cholesterol was associated with an increase in bodyweight of 1·03 kg (95% CI 0·24 to 1·82; and an increase of 0·006 (0·003 to 0·010) in waist-to-hip ratio, but we observed a potentially neutral association with BMI (0·11 kg/m², -0·09 to 0·30). Associations of the PCSK9 GS with glycaemia measures were 0·09 mmol/L (0·02 to 0·15) higher fasting plasma glucose, HbA 1c of 0·03% (-0·01 to 0·08; and for fasting insulin 0·00%, -0·06 to 0·07). SNP-specifi c forest plots are presented in the appendix. The estimates were similar when corrected for linkage disequilibrium (appendix), and no systematic deviations from an additive model were identifi ed (appendix). Finally, we noted an unanticipated eff ect on height (mean diff erence 0·008 m, 0·0008 to 0·015; appendix). Figure 3 shows the associations of individual PCSK9 variants and the GS with risk of type 2 diabetes. Using the PCSK9 GS, 1 mmol/L lower LDL cholesterol was associated with an increased risk of type 2 diabetes (OR 1·29, 95% CI 1·11 to 1·50). Exploring the PCSK9 associations with incident (appendix) or prevalent (appendix) type 2 diabetes separately showed directional concordance of this eff ect (incident type 2 diabetes OR 1·15, 0·76 to 1·72; prevalent type 2 diabetes OR 1·26, 0·88 to 1·80). Associations of individual SNPs with LDL cholesterol and risk of type 2 diabetes showed a doseresponse relation (fi gure 4).
Discussion
In this mendelian randomisation study, genetic variants in PCSK9, used as a proxy for pharmacological inhibition of PCSK9, were associated with lower LDL cholesterol concentration and increased risk of type 2 diabetes. The same variants were also associated with higher fasting glucose, bodyweight, and waist-to-hip ratio, and with directionally concordant but non-signifi cant associations for BMI and HbA 1c and a seemingly neutral association for fasting insulin. These results are in agreement with previous fi ndings for variants in the HMGCR gene encoding the target of statin drugs, with statins modestly increasing bodyweight and the risk of type 2 diabetes. 3 When scaled to 1 mmol/L lower LDL cholesterol, the risk for type 2 diabetes based on HMGCR variants 13 was an OR of 1·39 (95% CI 1·12 to 1·73), similar to the corresponding scaled estimate for this PCSK9 GS (1·29, 1·11 to 1·50), and similar to an estimate based on SNPs aff ecting LDL cholesterol selected from throughout the genome (1·27, 1·14 to 1·41). 5 However, eff ect estimates obtained from mendelian randomisation studies proxy lifetime exposure to natural genetic variation, and might therefore not directly translate to the size of eff ect of any corresponding pharmacological treatment introduced much later in life and thus for a shorter duration of time. 30 For example, in a meta-analysis of randomised controlled trials of statin treatment, 31 the OR for type 2 diabetes was 1·12 (95% CI 1·06 to 1·18).
In the case of statins, the treatment benefi t in terms of CHD risk reduction greatly outweighs any potential adverse eff ect on risk of type 2 diabetes, partly because the size of the risk reduction in CHD is greater than the risk increase in type 2 diabetes, and partly because the absolute risk of CHD in primary prevention populations eligible for statin treatment is greater than the absolute risk of type 2 diabetes. 32 A similarly precise risk assessment for PCSK9 inhibitors awaits results from larger and longer-term randomised trials. In a recent pooled analysis, 33 researchers reported that treatment with alirocumab was associated with an OR for type 2 diabetes of 0·89 (95% CI 0·62 to 1·28) compared with placebo, based on 133 type 2 diabetes events.
Variants that aff ect circulating LDL cholesterol have been reported previously to aff ect the probability of being prescribed a lipid-lowering drug. 34 We were unable to account for this eff ect in the analysis because prescription data for these treatments were often not available, and when they were recorded they were only available for a single follow-up point. For lipid-lowering treatments, one record of treatment does not properly refl ect the time-varying therapy received, and adjusting for only a single record when in fact treatment varies over followup might increase bias. 35 Typically, diabetes drug treatments are much less variable over time and correction for this treatment might seem advisable; however, because of the strong correlation between history of type 2 diabetes and use of type 2 diabetesrelated drugs, any correction for the latter would essentially correct for prevalent type 2 diabetes as well. Importantly, any eff ect of lipid-lowering drug therapy would attenuate rather than infl ate any associations.
We have previously reported examples of common variants in genes encoding a protein drug target mimicking the on-target eff ects of pharmacological interventions on biomarkers and disease outcomes in type, direction, and relative size. 3, 36, 37 However, such analyses cannot predict off -target eff ects of treatments. We refer to on-target eff ects as those that are due to a drug eff ect on the intended target (in this case PCSK9) and off -target eff ects as those that might occur because of the drug also binding to an unintended target (in this case, any target other than PCSK9). Although monoclonal antibody therapeutics are often highly specifi c, perhaps more so than small molecule therapeutics, they retain the potential for off -target eff ects. Hence, in the presence of off -target eff ects, results from ongoing randomised controlled trials could diff er from the genetic associations reported here.
Our main fi ndings are based on four PCSK9 SNPs in combination and scaled to 1 mmol/L lower LDL cholesterol. This approach assumes additive eff ects across the SNPs, an assumption that held well in sensitivity analyses. A potentially unobserved non-additive eff ect might explain why we identifi ed a genetic association with fasting glucose and a concordant (although nonsignifi cant) association with HbA 1c , whereas fasting Eff ect estimates are presented as odds ratios (ORs) for the incidence or prevalence of type 2 diabetes, with 95% CIs. Associations were scaled to a 1 mmol/L reduction in LDL cholesterol. SNP-specifi c results are pooled by use of a fi xed-eff ect model; weighted gene-centric score (GS) models combining all four SNP-specifi c estimates are presented as fi xed-eff ect and random-eff ects estimates. The size of the black dots representing the point estimates is proportional to the inverse of the variance. Between-SNP heterogeneity was measured as a two-sided Q-test (χ²) and an I2 with one-sided 97·5% CI. Results from individual participant data are supplemented by repository data from the Diabetes Genetics Replication and Meta-analysis consortium. Although concordant with fasting glucose, the HbA 1c association was non-signifi cant in the collected data, which might be related to the large amount of heterogeneity between the four SNPs (upper-bound I² 72%). Interestingly, the association of the PCSK9 GS with BMI was smaller than that with bodyweight, which might be (partially) explained by a slightly greater average height among individuals with PCSK9 variants associated with lower LDL cholesterol concentrations. A further potential reason for the slight discrepancy between the BMI and bodyweight associations could be the greater heterogeneity in the associations of PCSK9 SNPs with BMI than with weight. Notably, the GS eff ect estimates were often driven by a large eff ect of SNP rs11591147; as our doseresponse analysis shows (fi gure 4), the larger infl uence of this SNP appropriately refl ects the proportionally larger LDL cholesterol eff ect of this SNP. Finally, we did not have access to measures of PCSK9 concentration in this analysis, but others 40 have shown associations between common and rare PCSK9 alleles (including some of the same SNPs used here) and circulating PCSK9 concentrations.
Setting aside associations with glycaemia and weight, risk of type 2 diabetes could also be increased because lifelong exposure to genetic variation in PCSK9 might reduce mortality, making it conceivable that individuals with these variants survive longer and hence have more time to develop type 2 diabetes. However, whether PCSK9 genotype reduces mortality has not be conclusively shown. 8, 41 Irrespective of the nature of the PCSK9 association with type 2 diabetes, large randomised trials should determine whether this relation also holds for PCSK9 monoclonal antibodies.
In a recent study, 13 investigators used a single SNP in PCSK9 and also reported evidence of an association with type 2 diabetes (OR 1·19, 95% CI 1·02 to 1·38; per 1 mmol/L reduction in LDL cholesterol). In the present study, we incorporated data from four SNPs, instead of a single SNP, in a PCSK9 gene score with participant data from 50 studies supplemented by large genetic consortia and are able to confi rm their results, and also show this increase in type 2 diabetes risk is likely to be related to PCSK9-related increases in bodyweight and glucose. Previous studies of LDL cholesterol lowering HMGCR 3 and NPC1L1 13 variants (encoding pharmacological targets of statins and ezetimibe, respectively) and more widely on LDL cholesterol-lowering variants from multiple GWAS-associated loci, 5 as well as analyses of patients with monogenic hypercholesterolaemia, 6 have provided evidence of a link between LDL cholesterol and type 2 diabetes, compatible with the fi ndings from the present study. However, it is far from certain that all LDL cholesterol-lowering interventions will increase risk of type 2 diabetes, as not all share the same mechanism of action. The major site of both statins and PCSK9 inhibitors is thought to be the liver, through increased cellular membrane expression of the LDL receptor. The liver is also the site of action of the investigational apolipoprotein B antisense oligonucleotide mipomersen, whereas ezetimibe, the other licensed LDL cholesterol lowering drug, acts in the intestine to limit LDL cholesterol absorption. A potential unifying mechanism might be pancreatic β cell LDL receptor upregulation, increased lipid accumulation, and β cell dysfunction, 6 but this suggestion will need to be tested experimentally.
In conclusion, genetic variants in PCSK9 that associate with lower concentrations of LDL cholesterol are also associated with a modestly higher risk of type 2 diabetes and with associated diff erences in measures of glycaemia and bodyweight. Investigators of ongoing and future randomised controlled trials of PCSK9 inhibitors should carefully monitor changes in metabolic markers, including bodyweight and glycaemia, and the incidence of type 2 diabetes in study participants. Genetic studies of the type used here could be more widely used to interrogate the safety and effi cacy of novel drug targets. 
